Unusual Cancers of Childhood Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (08/07/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Head and Neck Cancers

Added text about the APEC1621 (NCT03155620) trial as a treatment option under clinical evaluation for nasopharyngeal carcinoma.

Added Treatment Options Under Clinical Evaluation as a new subsection for esthesioneuroblastoma.

Added text to state that larger tumor size, extrathyroidal extension, and multifocal disease are associated with increased risk of nodal metastases (cited Kim et al. as reference 79).

Added text to state that larger tumor size, extrathyroidal extension, and multifocal disease are associated with increased risk of nodal metastases.

Revised text about postoperative staging and long-term surveillance for thyroid nodules and differentiated thyroid cancer in children and adolescents.

Added text to state that while rare, late effects of iodine I 131 treatment include salivary gland dysfunction, bone marrow suppression, pulmonary fibrosis, and second malignancies (cited Albano et al. as reference 88).

Added Treatment Options Under Clinical Evaluation as a new subsection for recurrent papillary and follicular (differentiated) thyroid carcinoma.

Added Treatment Options Under Clinical Evaluation as a new subsection for medullary thyroid carcinoma.

Added Treatment Options Under Clinical Evaluation as a new subsection for oral cavity cancer.

Added Treatment Options Under Clinical Evaluation as a new subsection for salivary gland tumors.

Added Treatment Options Under Clinical Evaluation as a new subsection for laryngeal cancer.

Added text about the APEC1621 (NCT03155620) trial as a treatment option under clinical evaluation for midline tract carcinoma involving the NUT gene.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Other Rare Childhood Cancers

Next section >
About This PDQ Summary